Segel I. Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady
State Enzyme Systems. New York: Wiley Interscience; 1993.
Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the
organic anion transporting polypeptide 2 (oatp2/oatp1b1:Slc21a6)-mediated hepatic
uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism
of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil.
J Pharmacol Exp Ther 2004;311:228–236.
Shou M. Kinetic analysis for multiple substrate interaction at the active site of
cytochrome P450. Methods Enzymol 2002;357:261–276.
ShouM,LinY,LuP,TangC,MeiQ,CuiD,TangW,NguiJS,LinCC,SinghR,WongBK,
Yergey JA, Lin JH, Pearson PG, Baillie TA, Rodrigues AD, Rushmore TH. Enzyme
kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2001;2:17–36.
Silverman R. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology.
Boca Raton, FL: CRC Press; 1988.
Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa
M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St John’s
wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther
2001;70:518–524.
Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm
Sci 2005;94:1169–1186.
Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz
JS, Greenblatt DJ. Microsomal protein concentration modifies the apparent inhibitory
potency of CYP3A inhibitors. Drug Metab Dispos 2002;30: 1441–1445.
Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess
drug metabolism/transporter interaction potential-toward a consensus. Clin
Pharmacol Ther 2001;70:103–114.
Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt
DJ. Comparison between cytochrome P450 (CYP) content and relative activity
approaches to scaling from cDNA-expressed CYPs to human liver microsomes:
ratios of accessory proteins as sources of discrepancies between the approaches. Drug
Metab Dispos 2000;28:1493–1504.
Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug
Metab Dispos 2004;32:647–660.
Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E. Human
constitutive androstane receptor mediates induction of CYP2B6 gene expression by
phenytoin. J Biol Chem 2004;279:29295–29301.
Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-
metabolising enzymes. Clin Pharmacokinet 2003;42:1331–1357.
Westin S, Heyman RA, Martin R. FXR, a therapeutic target for bile acid and lipid
disorders. Mini Rev Med Chem 2005;5:719–727.
Wienkers LC. Problems associated within vitro assessment of drug inhibition of
CYP3A4 and other P-450 enzymes and its impact on drug discovery. J Pharmacol
Toxicol Methods 2001;45:79–84.
Wienkers LC, Heath TG. Predictingin vivodrug interactions fromin vitro drug
discovery data. Nat Rev Drug Discov 2005;4:825–833.
REFERENCES 135